Evidence of progressive multifocal leukoencephalopathy (PML) identified on the pretreatment magnetic resonance imaging (MRI)
History of progressive multifocal leukoencephalopathy (PML)
Patients with a known John Cunningham (JC) virus infection and/or progressive multifocal leukoencephalopathy (PML) are not eligible
History of autoimmune disease or of confirmed progressive multifocal leukoencephalopathy
History of progressive multifocal leukoencephalopathy (PML)
History of progressive multifocal leukoencephalopathy (PML)
Patients must not have known John Cunningham (JC) virus infection and/or progressive multifocal leukoencephalopathy (PML)
History of progressive multifocal leukoencephalopathy (PML).
History of progressive multifocal leukoencephalopathy (PML)
Participants with known history of pancreatitis or progressive multifocal leukoencephalopathy (PML)
History of progressive multifocal leukoencephalopathy (PML)
Present or history of progressive multifocal leukoencephalopathy (PML)
Participants with a history of progressive multifocal leukoencephalopathy
History of progressive multifocal leukoencephalopathy
History of or current diagnosis of progressive multifocal leukoencephalopathy (PML)
Known human immunodeficiency virus (HIV) or hepatitis B positivity or prior progressive multifocal leukoencephalopathy (PML)
History of progressive multifocal leukoencephalopathy (PML)
History of progressive multifocal leukoencephalopathy
History of progressive multifocal leukoencephalopathy (PML)
History of progressive multifocal leukoencephalopathy (PML)
Has active cerebral/meningeal disease, active cytomegalovirus (CMV) colitis, or signs and symptoms of progressive multifocal leukoencephalopathy (PML) or any history of PML.
Participants with history of confirmed progressive multifocal leukoencephalopathy (PML)
History of progressive multifocal leukoencephalopathy
History of progressive multifocal leukoencephalopathy
Present or history of progressive multifocal leukoencephalopathy (PML)
History of progressive multifocal leukoencephalopathy
Cerebral/meningeal disease, including signs and symptoms of progressive multifocal leukoencephalopathy (PML)
Participants with a history of confirmed progressive multifocal leukoencephalopathy (PML)
History of progressive multifocal leukoencephalopathy (PML)
Known active cerebral/meningeal disease, including signs or symptoms of progressive multifocal leukoencephalopathy (PML);
Participants with a history of confirmed progressive multifocal leukoencephalopathy (PML)
History of progressive multifocal leukoencephalopathy (PML).
In subjects with AITL, evidence of meningeal or cerebral disease or a history of progressive multifocal leukoencephalopathy
History of progressive multifocal leukoencephalopathy (PML)
Known active cerebral/meningeal disease, including signs or symptoms of progressive multifocal leukoencephalopathy (PML) or any history of PML
Known cerebral/meningeal disease, including history of progressive multifocal leukoencephalopathy
Patients with history of confirmed progressive multifocal leukoencephalopathy
Known John Cunningham (JC) virus infection and/or progressive multifocal leukoencephalopathy (PML)
Active cerebral/meningeal disease related to the underlying malignancy
Known cerebral/meningeal disease
Patients with recent cerebral hemorrhage
Patients with tumors involving the cerebellum or both cerebral hemispheres
Has a history of spontaneous or tumor-related cerebral hemorrhage; or has cerebral hemorrhage as determined by the screening fludeoxyglucose F-18 (FDG)-PET-computed tomography (CT) and MRI; this does not include stable post-operative blood products seen on a gradient echo MRI sequence
Active cerebral/meningeal disease related to the underlying malignancy
Cerebral edema, grade 3 or greater prior to surgery
Known cerebral/meningeal disease
Patients with cerebral metastases
Documented cerebral infarction within past 12 months
Patients with cerebral or systemic vasculopathy:
Patients with cerebral metastases
Subjects must not have clinically active cerebral metastases.
Cerebral/meningeal disease related to the underlying malignancy that has not been definitively treated
Active cerebral/meningeal disease related to the underlying malignancy.
Documented history of a cerebral vascular event
Known central nervous system (CNS) lymphomas; Active cerebral/meningeal disease related to the underlying malignancy
Cerebral/meningeal disease related to the underlying malignancy
Known active cerebral/meningeal lymphoma
Patients with known cerebral or meningeal involvement by lymphoma are excluded
Phase 2: Clinically active cerebral melanoma metastases. Subjects with up to 3 cerebral metastases, and neurological performance status of 0 may be enrolled, provided that all lesions have been adequately treated with stereotactic radiation therapy, craniotomy, or Gamma knife therapy, with no evidence of progression, and have not required steroids, for at least 2 months prior to enrollment.
Clinically active cerebral metastases.
Cerebral/meningeal disease related to the underlying malignancy
Known cerebral or meningeal disease
Known cerebral/meningeal disease
No evidence of cerebral edema
Cerebral/meningeal disease related to underlying malignancy
Cardio or cerebral vascular event within 6 months
Known intra-cerebral disease or brain mets
Cerebral/meningeal disease related to the underlying malignancy, unless definitively treated.
Subjects with a history of NF-1 related cerebral vascular anomaly (such as Moyamoya).
Known cerebral/meningeal disease.
Cerebral vascular accident
Documented cerebral metastasis
Prior resection of cerebral metastases
Patients with recent cerebral hemorrhage
Patients with recent cerebral hemorrhage
